Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.PMID:38401525 | DOI:10.1016/j.biopha.2024.116299 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 24, 2024 Category: Drugs & Pharmacology Authors: Sara Salvador-Mart ín Gianluca Rubbini Perceval Vellosillo Paula Zapata-Cobo Marta Velasco Laura M Palomino Susana Clemente Oscar Segarra Ana Moreno- Álvarez Ana Fern ández-Lorenzo Bego ña Pérez-Moneo Montserrat Montraveta Cesar S ánchez Mar Tol ín Source Type: research
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
CONCLUSIONS: We identified 102 differentially expressed genes involved in the response to anti-TNF drugs in children with IBDs and validated CEACAM8, LCN2, LTF2, and PRTN3. Genes participating in defense response to Gram-negative bacterium, serine-type endopeptidase activity, and transcriptional misregulation in cancer are good candidates for anticipating the response to anti-TNF drugs in children with IBDs.PMID:38401525 | DOI:10.1016/j.biopha.2024.116299 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 24, 2024 Category: Drugs & Pharmacology Authors: Sara Salvador-Mart ín Gianluca Rubbini Perceval Vellosillo Paula Zapata-Cobo Marta Velasco Laura M Palomino Susana Clemente Oscar Segarra Ana Moreno- Álvarez Ana Fern ández-Lorenzo Bego ña Pérez-Moneo Montserrat Montraveta Cesar S ánchez Mar Tol ín Source Type: research
Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report
We report an Asian patient with a 16-year-history of GPP and ACH with marked pustulosis on the nail bed and onychodystrophy. He received conventional systemic regimen acitretin, cyclosporine and biologics adalimumab and secukinumab, but experienced relapse for skin lesions and refractory for nail lesions. He was then treated with a single dose of spesolimab in combination with secukinumab, which resulted in skin clearance and nearly complete resolution of nail lesions over a 32-week period. Our observation suggests that spesolimab should be considered for the treatment of ACH, especially in the patients with intractable na...
Source: Frontiers in Immunology - February 23, 2024 Category: Allergy & Immunology Source Type: research
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto
(Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 22, 2024 Category: Rheumatology Source Type: research
Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography
Eye, Published online: 20 February 2024; doi:10.1038/s41433-024-02975-9Effect of adalimumab on choroidal thickness and choroidal vascularity index in eyes with non-infectious uveitis using enhanced-depth imaging optical coherence tomography (Source: Eye)
Source: Eye - February 20, 2024 Category: Opthalmology Authors: Cem Evereklioglu Elif Er Arslantas Hidayet Sener Zeynep Akkul Kamran Gahramanov Duygu Gulmez Sevim Osman Ahmet Polat Fatih Horozoglu Source Type: research
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto
(Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 19, 2024 Category: Rheumatology Source Type: research
Infliximab for maintenance of medically-induced remission in Crohn's disease
CONCLUSIONS: Infliximab is probably more effective in preventing clinical relapse than placebo (moderate-certainty evidence). Infliximab in combination with purine analogues is probably more effective in preventing clinical and endoscopic relapse than purine analogues alone (moderate-certainty evidence). No conclusions can be drawn regarding prevention of loss of clinical response, occurrence of withdrawals due to adverse events, or total adverse events due to very low-certainty evidence for both of these comparisons. There may be little or no difference in prevention of clinical relapse, withdrawal due to adverse events o...
Source: Cochrane Database of Systematic Reviews - February 19, 2024 Category: General Medicine Authors: Morris Gordon Vassiliki Sinopoulou Anthony K Akobeng Arni Sarian Gordon William Moran Source Type: research
Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF- α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features
Biol Chem. 2024 Feb 20. doi: 10.1515/hsz-2023-0370. Online ahead of print.ABSTRACTIn this work we have generated cattle-derived chimeric ultralong CDR-H3 antibodies targeting tumor necrosis factor α (TNF-α) via immunization and yeast surface display. We identified one particular ultralong CDR-H3 paratope that potently neutralized TNF-α. Interestingly, grafting of the knob architecture onto a peripheral loop of the CH3 domain of the Fc part of an IgG1 resulted in the generation of a TNF-α neutralizing Fc (Fcknob) that did not show any potency loss compared with the parental chimeric IgG format. Eventually, grafting this...
Source: Biological Chemistry - February 19, 2024 Category: Chemistry Authors: Paul Arras Jasmin Zimmermann Britta Lipinski Bernhard Valldorf Andreas Evers Desislava Elter Simon Krah Achim Doerner Enrico Guarnera Vanessa Siegmund Harald Kolmar Lukas Pekar Stefan Zielonka Source Type: research
Infliximab for maintenance of medically-induced remission in Crohn's disease
CONCLUSIONS: Infliximab is probably more effective in preventing clinical relapse than placebo (moderate-certainty evidence). Infliximab in combination with purine analogues is probably more effective in preventing clinical and endoscopic relapse than purine analogues alone (moderate-certainty evidence). No conclusions can be drawn regarding prevention of loss of clinical response, occurrence of withdrawals due to adverse events, or total adverse events due to very low-certainty evidence for both of these comparisons. There may be little or no difference in prevention of clinical relapse, withdrawal due to adverse events o...
Source: Cochrane Database of Systematic Reviews - February 19, 2024 Category: General Medicine Authors: Morris Gordon Vassiliki Sinopoulou Anthony K Akobeng Arni Sarian Gordon William Moran Source Type: research
Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF- α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features
Biol Chem. 2024 Feb 20. doi: 10.1515/hsz-2023-0370. Online ahead of print.ABSTRACTIn this work we have generated cattle-derived chimeric ultralong CDR-H3 antibodies targeting tumor necrosis factor α (TNF-α) via immunization and yeast surface display. We identified one particular ultralong CDR-H3 paratope that potently neutralized TNF-α. Interestingly, grafting of the knob architecture onto a peripheral loop of the CH3 domain of the Fc part of an IgG1 resulted in the generation of a TNF-α neutralizing Fc (Fcknob) that did not show any potency loss compared with the parental chimeric IgG format. Eventually, grafting this...
Source: Biological Chemistry - February 19, 2024 Category: Chemistry Authors: Paul Arras Jasmin Zimmermann Britta Lipinski Bernhard Valldorf Andreas Evers Desislava Elter Simon Krah Achim Doerner Enrico Guarnera Vanessa Siegmund Harald Kolmar Lukas Pekar Stefan Zielonka Source Type: research
A Rare Case of Varicella Zoster Infection in Hemorrhoids in a Patient With Inflammatory Bowel Disease
We present a case of a 41-year-old man with a history of ulcerative colitis on adalimumab who presented with anal lesions. He was diagnosed with hemorrhoids and surgically treated. Microscopic examination confirmed the diagnosis of hemorrhoids. However, foci of epithelium with viral cytopathic effects were noted. A varicella zoster virus (VZV)-specific immunostain was positive in the areas of interest confirming the diagnosis of the VZV infection limited to the hemorrhoids. Combined herpes simplex virus type 1 and 2 (HSV 1 and HSV 2) immunostain was also performed and was negative. Anal herpes has been widely described in ...
Source: Herpes - February 14, 2024 Category: Infectious Diseases Authors: Hanna Siatecka Sarah Al-Awami Ahsan Siddiqi A Hafeez Diwan Source Type: research
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
The study aimed to examine the direct medical cost and impact of tocilizumab (TOZ) versus adalimumab (ADM) and etanercept (ETC) on reducing the levels of two inflammatory markers (e.g., C-reactive protein (CRP... (Source: Cost Effectiveness and Resource Allocation)
Source: Cost Effectiveness and Resource Allocation - February 14, 2024 Category: Health Management Authors: Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi and Yazed AlRuthia Tags: Research Source Type: research
Neues zum Beh çet-Syndrom
Laryngorhinootologie DOI: 10.1055/a-2249-2116
Immunpathogenese und Genetik Auch beim BS spielt die Neutrophilen-
(Hyper-)Aktivierung und die daraus hervorgehende NETosis eine wichtige Rolle.
Klinische Befunde Neben den 4 Kardinalsymptomen – nämlich rezidivierende orale Aphthen, genitale Aphthen sowie Haut- und Augenläsionen – bietet das Krankheitsbild zahlreiche weitere Manifestationen, die häufig eine interdisziplinäre Zusammenarbeit erfordern. Dies gilt neben der Augenbeteiligung, die bei inadäquater Behandlung immer noch zur Erblindung führen kann, insbesondere auch für intestinale und zere...
Source: Laryngo- Rhino- Otologie - February 8, 2024 Category: ENT & OMF Authors: Xenitidis, Theodoros Henes, J örg Christoph Tags: Übersicht Source Type: research
Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry
Conclusions
No differences in DAS28-remission were found between the study drugs and adalimumab as first biologic in patients with RA, independently of the BMI cohort. We did not find evidence that treatment with abatacept increased the likelihood of remission compared with adalimumab among obese patients with RA. (Source: BMJ Open)
Source: BMJ Open - February 8, 2024 Category: General Medicine Authors: Vallejo-Yagüe, E., Burkard, T., Finckh, A., Burden, A. M., On behalf of the clinicians and patients of the Swiss Clinical Quality Management Program Tags: Open access, Rheumatology Source Type: research
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study
Br J Dermatol. 2024 Feb 2:ljae042. doi: 10.1093/bjd/ljae042. Online ahead of print.NO ABSTRACTPMID:38305415 | DOI:10.1093/bjd/ljae042 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - February 2, 2024 Category: Dermatology Authors: Hans Christian Ring Jonathan Thorsen Brian Kirby John R Ingram Nana Aviaaja Lippert Rosen ø Nikolaj Holgersen Valdemar W Nielsen David Nikolai Thein Aagaard Julia-Tatjana Maul Jashin J Wu Jacob P Thyssen Alexander Egeberg Simon F Thomsen Source Type: research
